Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A double‐blind placebo‐controlled trial of the calcium antagonist Nimodipine in 10 patients with multi‐infarct dementia (MID) shows that there is no improvement when compared with 10 patients on placebo assessed by clinical ratings and sequential NMR imaging. The value of repeated NMR imaging in measuring changes in MID is described. Copyright © 1988 John Wiley & Sons, Ltd.

Original publication

DOI

10.1002/gps.930030206

Type

Journal article

Journal

International Journal of Geriatric Psychiatry

Publication Date

01/01/1988

Volume

3

Pages

99 - 105